Turning cold tumors hot: from molecular mechanisms to clinical applications

2022/05/25 by Jiahui Zhang, Di Huang, Phei Er Saw +1 · 1 voice · 558 citations
Immunology and Microbiology · Medicine · #Antigen #Bioinformatics #Biology #Blockade #Cancer Immunotherapy and Biomarkers #Genetics #Immune Cell Function and Interaction #Immune checkpoint #Immune system #Immunology #Immunophenotyping #Immunotherapy #Immunotherapy and Immune Responses #Receptor

paper · doi:10.1016/j.it.2022.04.010

published in Trends in Immunology 43(7), 523-545 (Elsevier BV)

openalex publication_date 2022/05/25 · openalex created_date 2025/10/10 · openalex updated_date 2026/08/04

Cited by

• Targeting DHX9 Triggers Tumor-Intrinsic Interferon Response and Replication Stress in Small Cell Lung Cancer
• Expression of IMPACT Curtails Metabolic Plasticity and Augments NK Cell Killing to Abrogate Metastatic Growth
• Stepwise epigenetic signal integration drives adaptive programming of cytotoxic lymphocytes
• cGAS/STING-mediated γδ T cell recruitment drives radioresistance: implications for improving radioimmunotherapy outcomes
• Gastrointestinal cancer: molecular pathogenesis and targeted therapy
• Drug resistance in cancer: molecular mechanisms and emerging treatment strategies
• HSV-1 as a gene delivery platform for cancer gene therapy
• Nanoparticle-Based Drug Delivery Systems Targeting Tumor Microenvironment for Cancer Immunotherapy Resistance: Current Advances and Applications. [europepmc]
• Atypical chemokine receptors: emerging therapeutic targets in cancer. [europepmc]
• TAM-targeted reeducation for enhanced cancer immunotherapy: Mechanism and recent progress. [europepmc]
• Medicinal plant-derived mtDNA via nanovesicles induces the cGAS-STING pathway to remold tumor-associated macrophages for tumor regression. [europepmc]
• Photon-Controlled Pyroptosis Activation (PhotoPyro): An Emerging Trigger for Antitumor Immune Response. [europepmc]
• Immunogenic cell death in cancer immunotherapy. [europepmc]
• Single-cell omics traces the heterogeneity of prostate cancer cells and the tumor microenvironment. [europepmc]
• Molecular mechanisms of immunotherapy resistance in triple-negative breast cancer. [europepmc]
• Neoadjuvant adebrelimab in locally advanced resectable esophageal squamous cell carcinoma: a phase 1b trial. [europepmc]
• Inhibition of CDC20 potentiates anti-tumor immunity through facilitating GSDME-mediated pyroptosis in prostate cancer. [europepmc]
• Synergistic efficacy of simultaneous anti-TGF-β/VEGF bispecific antibody and PD-1 blockade in cancer therapy. [europepmc]
• The future of affordable cancer immunotherapy. [europepmc]
• Ablation of ERO1A induces lethal endoplasmic reticulum stress responses and immunogenic cell death to activate anti-tumor immunity. [europepmc]
• Tumor mutation burden in the prognosis and response of lung cancer patients to immune-checkpoint inhibition therapies. [europepmc]
• CD8 T-cell subsets: heterogeneity, functions, and therapeutic potential. [europepmc]
• The molecular classification of cancer-associated fibroblasts on a pan-cancer single-cell transcriptional atlas. [europepmc]
• T-cell infiltration and its regulatory mechanisms in cancers: insights at single-cell resolution. [europepmc]
• Peptide-Driven Proton Sponge Nano-Assembly for Imaging and Triggering Lysosome-Regulated Immunogenic Cancer Cell Death. [europepmc]
• Overcoming cold tumors: a combination strategy of immune checkpoint inhibitors. [europepmc]
• Current Landscape of Cancer Immunotherapy: Harnessing the Immune Arsenal to Overcome Immune Evasion. [europepmc]
• Tumor battlefield within inflamed, excluded or desert immune phenotypes: the mechanisms and strategies. [europepmc]
• Tryptophan 2,3-dioxygenase-positive matrix fibroblasts fuel breast cancer lung metastasis via kynurenine-mediated ferroptosis resistance of metastatic cells and T cell dysfunction. [europepmc]
• Cold and hot tumors: from molecular mechanisms to targeted therapy. [europepmc]
• Enhancing immuno-oncology investigations through multidimensional decoding of tumor microenvironment with IOBR 2.0. [europepmc]
• Elevated protein lactylation promotes immunosuppressive microenvironment and therapeutic resistance in pancreatic ductal adenocarcinoma. [europepmc]

Discussions

• The conversion of immunologically cold to immunologically hot tumors is a major area of interest within immuno-oncology: doi.org/10.1016/j.it... Enter: this study. First, the team saw that people who [bsky, 25 points, 1 comments]